2.15
2.15 (0%)
As of Feb 14, 2025
Inovio Pharmaceuticals, Inc. [INO]
Source:
Company Overview
Inovio Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 8584103134 |
| Industry | manufacturing |
| CEO | Jacqueline E. Shea |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.2 |
| Operating Profit | $-112.4 |
| Net Income | $-107.3 |
| Net Cash | $51.5 |
Profit Ratios
| Gross Margin | $0.2 |
| Operating Margin | -51,616.9 |
| Profit as % of Revenues | -0.2% |
| Profit as % of Assets | -75.5% |
| Profit as % of Stockholder Equity | -156.6% |
Management Effectiveness
| Return on Equity | -156.6% |
| Return on Assets | -94.8% |
| Turnover Ratio | 0.2% |
| EBITA | $-112.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $113.2 |
| Total Liabilities | $44.7 |
| Operating Cash Flow | $-104.1 |
| Investing Cash Flow | $104.1 |
| Financing Cash Flow | $51.5 |
